Lisanti Capital Growth LLC Sells 20,320 Shares of Glaukos Co. (NYSE:GKOS)

Lisanti Capital Growth LLC lowered its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 48.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,330 shares of the medical instruments supplier's stock after selling 20,320 shares during the quarter. Lisanti Capital Growth LLC's holdings in Glaukos were worth $2,779,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GKOS. Crossmark Global Holdings Inc. lifted its position in shares of Glaukos by 15.8% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 4,051 shares of the medical instruments supplier's stock valued at $527,000 after acquiring an additional 554 shares during the last quarter. Amalgamated Bank raised its stake in shares of Glaukos by 4.5% in the third quarter. Amalgamated Bank now owns 15,926 shares of the medical instruments supplier's stock valued at $2,075,000 after acquiring an additional 679 shares during the last quarter. New York State Teachers Retirement System increased its stake in shares of Glaukos by 0.4% in the third quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier's stock valued at $6,272,000 after buying an additional 200 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in shares of Glaukos by 6.0% during the third quarter. State of Alaska Department of Revenue now owns 31,357 shares of the medical instruments supplier's stock valued at $4,085,000 after acquiring an additional 1,785 shares during the period. Finally, Louisiana State Employees Retirement System lifted its position in Glaukos by 5.1% during the 3rd quarter. Louisiana State Employees Retirement System now owns 26,600 shares of the medical instruments supplier's stock valued at $3,465,000 after purchasing an additional 1,300 shares during the period. Hedge funds and other institutional investors own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

GKOS has been the subject of a number of recent research reports. Wells Fargo & Company boosted their target price on Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Needham & Company LLC increased their price target on Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a report on Thursday, August 1st. BTIG Research increased their price objective on shares of Glaukos from $131.00 to $139.00 and gave the company a "buy" rating in a research note on Wednesday, August 28th. Stifel Nicolaus lifted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Finally, StockNews.com upgraded shares of Glaukos from a "sell" rating to a "hold" rating in a research report on Monday, October 21st. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $134.55.

Glaukos Stock Up 0.9 %

Shares of GKOS stock traded up $1.29 on Monday, hitting $143.04. The stock had a trading volume of 423,636 shares, compared to its average volume of 580,128. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $145.51. The stock has a market cap of $7.89 billion, a price-to-earnings ratio of -46.94 and a beta of 1.02. The business has a 50 day moving average of $129.89 and a 200 day moving average of $121.05. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.67.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm's revenue was up 23.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.50) earnings per share. As a group, analysts expect that Glaukos Co. will post -1.96 EPS for the current year.

Insider Activity

In related news, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares of the company's stock, valued at $14,198,425.93. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,525 shares of company stock valued at $2,142,029. 6.40% of the stock is currently owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.